Advertisement

Topics

Latest "CAFC Affirms Apotex Biosimilars Infringe Amgen Patent" News Stories

06:57 EDT 24th April 2018 | BioPortfolio

Here are the most relevant search results for "CAFC Affirms Apotex Biosimilars Infringe Amgen Patent" found in our extensive news archives from over 250 global news sources.

More Information about CAFC Affirms Apotex Biosimilars Infringe Amgen Patent on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about CAFC Affirms Apotex Biosimilars Infringe Amgen Patent for you to read. Along with our medical data and news we also list CAFC Affirms Apotex Biosimilars Infringe Amgen Patent Clinical Trials, which are updated daily. BioPortfolio also has a large database of CAFC Affirms Apotex Biosimilars Infringe Amgen Patent Companies for you to search.

Showing "CAFC Affirms Apotex Biosimilars Infringe Amgen Patent" News Articles 1–25 of 4,300+

Tuesday 24th April 2018

Axiron Drug Insight, 2018 [Report Updated: 14022018] Prices from USD $1000

IntroductionDelveInsight's pharmaceuticals report, "Axiron Drug Insight, 2018" highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global Market Assessment of the Axiron covering the historical global sales and also provides the Axiron sales estimation during the forecasted period 20182020. The report also co...


Adderall Drug Insight, 2018 [Report Updated: 14022018] Prices from USD $1000

IntroductionDelveInsight's pharmaceuticals report, "Adderall Drug Insight, 2018" highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global Market Assessment of the Adderall covering the historical global sales and also provides the Adderall sales estimation during the forecasted period 20182020. The report a...

GNI Group Initiates Phase I Study of F351 in USA

GNI USA, Inc., a wholly-owned subsidiary of GNI Group Ltd. (TOKYO:2160), announced the first subject was dosed in the F351 Phase I clinical trial taking place in New Jersey, USA. The primary objective of this trial is to understand the pharmacokinetics and safety of F351 in a diverse ethnic population to supplement the previous Phase I results obtained in ...


Peripheral Arterial Disease PAD/ Pulmonary Vascular Disease PVD Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

"Peripheral Arterial Disease PAD/ Pulmonary Vascular Disease PVD Pipeline Insight, 2018 report by DelveInsight offers comprehensive Insight of the pipeline under development therapeutics scenario and growth prospects across Peripheral Arterial Disease PAD/ Pulmonary Vascular Disease PVD development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equi...

Monday 23rd April 2018

Type 1 Lysophosphatidic Acid Receptor LPA1 Inhibitor Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

Type 1 Lysophosphatidic Acid Receptor LPA1 Inhibitor Pipeline Insight, 2018 report by DelveInsight offers comprehensive insights of the pipeline under development therapeutics scenario and growth prospects across Type 1 Lysophosphatidic Acid Receptor LPA1 Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from ...

Porphyria Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

"Porphyria Pipeline Insight, 2018 report by DelveInsight offers comprehensive Insight of the pipeline under development therapeutics scenario and growth prospects across Porphyria development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indi...

Glenmark Eyes Blockbuster Status For First In-House Biologic

Indian drug firm Glenmark Pharmaceuticals says it’s launching a Phase 2b clinical trial for its first biologic developed in-house, a...  

Express Scripts targets new migraine drugs to change U.S. pricing dynamic

LOS ANGELES (Reuters) - The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it.

Zurampic Drug Insight, 2018 [Report Updated: 14022018] Prices from USD $1000

IntroductionDelveInsight's pharmaceuticals report, "Zurampic Drug Insight, 2018" highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global Market Assessment of the Zurampic covering the historical global sales and also provides the Zurampic sales estimation during the forecasted period 20182020. The report a...

Will Biosimilars Lead To Better Biologics Manufacturing?

US FDA Commissioner Gottlieb is promising new policies to improve biologics manufacturing as part of agency’s action plan to accelerate...   

Opioid Use Disorder: Is Reduced Usage A Better Endpoint Than Abstinence?

Some at patient-focused drug development meeting argue that cutting opioid use should not be considered treatment failure and that medications...   

Ranexa API Insight,2018 [Report Updated: 14022018] Prices from USD $500

IntroductionDelveInsight's, Ranexa API Insight, 2018 report provides product and API manufacturers' details across the globe along with the location. The report gives the clear idea on the country wise DMF filed by worldwide companies related to Ranexa . The report also highlights the patent details of Ranexa . MethodologyThe report is built using data and information sourced from proprietary da...

Bacteremia Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

"Bacteremia Pipeline Insight, 2018 report by DelveInsight offers comprehensive Insight of the pipeline under development therapeutics scenario and growth prospects across Bacteremia development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated in...

Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns

Janssen and Bristol team to develop next-generation oral anticoagulant, while UCB buys Proximagen's nasal spray candidate and Duke spinout focused...    

Colorado BioScience Association Names New Board Members

Leaders represent CereScan, Ocugen, Prevacept Infection Control, Sharklet and Zimmer Biomet Colorado BioScience Association (CBSA) announces new members elected to its board of directors. The five new board members were introduced and approved during the organization’s annual board retreat on April 19. Newly appointed board members: ...

Michael Best Adds New Managing Partner and Intellectual Property Attorney in Raleigh

Michael Best is pleased to announce that Anthony Biller and Emily Haas have joined the firm’s Intellectual Property Practice Group in Raleigh. Biller joins as partner in addition to being named Managing Partner of the office, with Haas joining as a senior counsel. “We’re thrilled to welcome these talented attorneys to our Raleigh office,” ...

Fast And Furious: How The First-To-Market Advantage Is Shrinking

The competitive dynamics in the pharmaceutical sector appear to be intensifying, with second- and third-to-market drugs reaching the market faster...    

Flexible Biosimilar Development

NewsAs they are developed across a wider range of therapeutic areas, biosimilars will play a more important role by providing a greater choice of treatment options.

Merck KGa Receives Patent For CRISPR Technology In China

LONDON (dpa-AFX) - Merck KGa (MKGAY.PK) said that the Chinese Patent Office has issued a notice granting Merck's patent application for the company's CRISPR technology used in a genomic-integratio...

Spasticity Market Insight, Epidemiology and Market Forecast 2027 [Report Updated: 14022018] Prices from USD $6250

DelveInsight's "Spasticity Market Insight, Epidemiology and Market Forecast 2027" report provides a detailed analysis of the Spasticity epidemiology and market outlook for the 7MM.Markets Covered United States EU5 Germany, France, Italy, Spain, and the United Kingdom JapanStudy Period: 20162027Spasticity Understanding and Treatment AlgorithmThe market report provides the overview of the Spast...

Win-Win For Alnylam And Dicerna With RNAi Trade Secrets Settlement

Although Dicerna needs to make some payments to Alnylam to settle a patent infringement case, the company has avoided an...   

Plaque Psoriasis Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

"Plaque Psoriasis Pipeline Insight, 2018 report by DelveInsight offers comprehensive Insight of the pipeline under development therapeutics scenario and growth prospects across Plaque Psoriasis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, a...

AstraZeneca Seeks To Ward Off Brilinta Patent Infringer In India

An Indian court has blocked an alleged infringer of AstraZeneca';s patent pertaining to Brilinta (ticagrelor), but the case, some experts...   

Teva to Report First Quarter 2018 Financial Results on May 3, 2018

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its first quarter 2018 financial results on Thursday, May 3, 2018 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its first quarter 2018 results and overall business environment. A Question & Answ...

Pfizer Provides Update on Proposed Trastuzumab Biosimilar

Pfizer Inc. (NYSE:PFE) today announced that it received a Complete Response Letter (CRL) from the United States Food and Drug Administration (FDA) in response to the Biologics License Application for the company’s proposed trastuzumab biosimilar. In the CRL, the FDA highlighted the need for additional technical information. The additional requested infor...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks